Expert Perspectives - Nucala

Watch below to see Dr Neil Martin, a Consultant Chest Physician at the Glenfield Hospital, Leicester UK and a UK employee of GSK, present the types of patient profiles commonly seen in his own clinical practice who are eligible for Nucala.

Professor Peter Howarth, University of Southampton and Global Clinical Scientific Lead in Biologics (GSK), talks about eosinophil targeted therapies, what we understand about their role in depletion of eosinophils and their impact on reducing and depleting eosinophils in severe asthma.

Explore efficacy data

Footnotes

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older¹

Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within the first 3 injections.¹ The long-term safety and immunogenicity profile of Nucala was similar to that observed in placebo-controlled asthma trials²

The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in a pre-filled pen, pre-filled syringe or lyophilised powder. The licensed dose of Nucala in children aged 6-11 years is 40mg SC regardless of weight and available in lyophilised powder. The pre-filled formulations are not indicated in 6-11 year olds.¹

Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. These limitations are important when interpreting results: lack of comparator arm, differences in patient populations and data collection vs. randomised controlled trials.

References

  1. Nucala SmPC, 2020.
  2. Khurana S et al. Clin Ther 2019; 41:2041-2056

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

© 2020 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

PM-GB-MPL-WCNT-200037 | November 2020